{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:53:19Z","timestamp":1760266399040},"reference-count":25,"publisher":"Elsevier BV","issue":"8210","license":[{"start":{"date-parts":[[1981,1,1]],"date-time":"1981-01-01T00:00:00Z","timestamp":347155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[1981,1]]},"DOI":"10.1016\/s0140-6736(81)90115-x","type":"journal-article","created":{"date-parts":[[2003,10,11]],"date-time":"2003-10-11T13:31:46Z","timestamp":1065879106000},"page":"10-13","source":"Crossref","is-referenced-by-count":71,"title":["LONG-TERM T-CELL-MEDIATED IMMUNITY TO EPSTEIN-BARR VIRUS IN RENAL-ALLOGRAFT RECIPIENTS RECEIVING CYCLOSPORIN A"],"prefix":"10.1016","volume":"317","author":[{"given":"DorothyH.","family":"Crawford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JoanM.B.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Sweny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Janossy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.Victor","family":"Hoffbrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(81)90115-X_BIB1","first-page":"631","article-title":"Comparative study of in vitro and in vivo drug effects on cell-mediated cytotoxicity","volume":"31","author":"Borel","year":"1976","journal-title":"Immunology"},{"key":"10.1016\/S0140-6736(81)90115-X_BIB2","first-page":"1017","article-title":"Effects of the new anti-lymphocyte peptide cyclosporin A in animals","volume":"32","author":"Borel","year":"1977","journal-title":"Immunology"},{"key":"10.1016\/S0140-6736(81)90115-X_BIB3","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(79)92440-1","article-title":"Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadavaric organs: 32 kidneys, 2 pancreases, and 2 livers","volume":"ii","author":"Calne","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(81)90115-X_BIB4","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0140-6736(80)90881-8","article-title":"Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation","volume":"i","author":"Powles","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(81)90115-X_BIB5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/286609a0","article-title":"Suppression of in vitro lymphocyte reactivity by cyclosporin A: existence of a population of drug-resistant cytotoxic lymphocytes","volume":"286","author":"Horsburgh","year":"1980","journal-title":"Nature"},{"key":"10.1016\/S0140-6736(81)90115-X_BIB6","first-page":"67","article-title":"Effects of cyclosporin A on human lymphocytes in culture","volume":"1","author":"Leoni","year":"1978","journal-title":"J Clin Lab Immun"},{"key":"10.1016\/S0140-6736(81)90115-X_BIB7","first-page":"2601","article-title":"Effect of cyclosporin on human lymphocyte responses in vitro. I. CSA allows for the expression of allo-antigen-activated suppressor cells while preferentially inhibiting the induction of cytolytic effector lymphocytes in MLR","volume":"124","author":"Hess","year":"1980","journal-title":"J Immunol"},{"key":"10.1016\/S0140-6736(81)90115-X_BIB8","series-title":"Malignant tumors in organ transplant recipients","author":"Penn","year":"1970"},{"key":"10.1016\/S0140-6736(81)90115-X_BIB9","first-page":"1047","article-title":"Tumour incidence in human allograft recipients","volume":"11","author":"Penn","year":"1979","journal-title":"Transplant Proc"},{"key":"10.1016\/S0140-6736(81)90115-X_BIB10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM198008073030601","article-title":"Immunologic phenotype in 30 patients with diffuse large-cell lymphoma","volume":"303","author":"Warnke","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(81)90115-X_BIB11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0140-6736(80)90579-6","article-title":"Malignant lymphoma in cyclosporin-A-treated allograft recipients","volume":"i","author":"Bieber","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(81)90115-X_BIB12","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-67236-1_14","article-title":"The relationship of the virus to Burkitt's lymphoma","author":"Epstein","year":"1979"},{"key":"10.1016\/S0140-6736(81)90115-X_BIB13","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S0140-6736(80)92784-1","article-title":"Cyclosporin-A immunosuppression, Epstein-Barr antibody, and lymphoma","volume":"i","author":"Nagington","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(81)90115-X_BIB14","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S0140-6736(80)91800-0","article-title":"Epstein-Barr-virus nuclear antigenpositive lymphoma after cyclosporin-A treatment in patients with renal allograft","volume":"i","author":"Crawford","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(81)90115-X_BIB15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/ijc.2910080312","article-title":"The establishment of lymphoblastoid lines from adult and fetal human lymphoid cells and its dependence on EBV","volume":"8","author":"Nilsson","year":"1971","journal-title":"Int J Camcer"},{"key":"10.1016\/S0140-6736(81)90115-X_BIB16","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/infdis\/128.3.283","article-title":"Neutralizing antibodies to Epstein-Barr virus in healthy populations and patients with infectious mononucleosis","volume":"128","author":"Hewetson","year":"1973","journal-title":"J Infect Dis"},{"key":"10.1016\/S0140-6736(81)90115-X_BIB17","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/ijc.2910220604","article-title":"Long-term T cell-mediated immunity to Epstein Barr virus in man. I. Complete regression of virus-induced transformation of seropositive donor leucocytes","volume":"22","author":"Moss","year":"1978","journal-title":"Int J Cancer"},{"key":"10.1016\/S0140-6736(81)90115-X_BIB18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1073\/pnas.69.2.383","article-title":"Lupman M Epstein-Barr virus: Transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leucocytes","volume":"69","author":"Miller","year":"1972","journal-title":"Proc Nat Acad Sci USA"},{"key":"10.1016\/S0140-6736(81)90115-X_BIB19","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1128\/JB.91.3.1248-1256.1966","article-title":"Immunofluorescence in cells derived from Burkitt's lymphoma","volume":"91","author":"Henle","year":"1966","journal-title":"J Bact"},{"key":"10.1016\/S0140-6736(81)90115-X_BIB20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ijc.2910110302","article-title":"Cellular localisation of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines","volume":"11","author":"Reedman","year":"1973","journal-title":"Int J Cancer"},{"key":"10.1016\/S0140-6736(81)90115-X_BIB21","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/283865a0","article-title":"HLA-restricted T cell recognition of Epstein- Barr virus-infected B cells","volume":"283","author":"Rickinson","year":"1980","journal-title":"Nature"},{"key":"10.1016\/S0140-6736(81)90115-X_BIB22","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/ijc.2910230505","article-title":"Long-term T cell-mediated immunity to Epstein Barr virus in man. II. Components necessary for regression in virus-infected leucocyte cultures","volume":"23","author":"Rickinson","year":"1979","journal-title":"Int J Cancer"},{"key":"10.1016\/S0140-6736(81)90115-X_BIB23","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0140-6736(80)90457-2","article-title":"Cyclosporin A and Epstein-Barr virus","volume":"ii","author":"Bird","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(81)90115-X_BIB24","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1073\/pnas.72.4.1622","article-title":"Cytotoxic effector cells specific for B cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis","volume":"72","author":"Svedmyr","year":"1975","journal-title":"Proc Nat Acad Sci USA"},{"key":"10.1016\/S0140-6736(81)90115-X_BIB25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1146\/annurev.mi.31.100177.002225","article-title":"Recent progress in Epstein-Barr virus research","volume":"31","author":"Epstein","year":"1977","journal-title":"Ann Rev Microbiol"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014067368190115X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014067368190115X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T01:59:54Z","timestamp":1585187994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014067368190115X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1981,1]]},"references-count":25,"journal-issue":{"issue":"8210","published-print":{"date-parts":[[1981,1]]}},"alternative-id":["S014067368190115X"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(81)90115-x","relation":{},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[1981,1]]}}}